Serrano, Erik
Peters, John https://orcid.org/0009-0000-8564-3264
Wagner, Jesko https://orcid.org/0000-0001-9805-7192
Graham, Rebecca E
Chen, Zhenghao
Feng, Brian Y https://orcid.org/0000-0002-4208-8624
Miranda, Gisele
Kalinin, Alexandr A https://orcid.org/0000-0003-4563-3226
Vulliard, Loan
Tomkinson, Jenna https://orcid.org/0000-0003-2676-5813
Mattson, Cameron
Lippincott, Michael J
Kang, Ziqi https://orcid.org/0009-0003-2084-610X
Sitani, Divya https://orcid.org/0000-0001-5138-6108
Bunten, Dave
Seal, Srijit https://orcid.org/0000-0003-2790-8679
Carragher, Neil O https://orcid.org/0000-0001-5541-9747
Carpenter, Anne E https://orcid.org/0000-0003-1555-8261
Singh, Shantanu https://orcid.org/0000-0003-3150-3025
Marin Zapata, Paula A
Caicedo, Juan C https://orcid.org/0000-0002-1277-4631
Way, Gregory P https://orcid.org/0000-0002-0503-9348
Funding for this research was provided by:
HHS | NIH | U.S. National Library of Medicine (T15LM009451)
HHS | NIH | U.S. National Library of Medicine (5T15LM007359)
HHS | NIH | National Institute of General Medical Sciences (R35 GM122547)
Human Frontier Science Program (RGY0081/2019)
Gilbert Family Foundation (923014)
Alex's Lemonade Stand Foundation for Childhood Cancer (23-28306)
American Heart Association (24CSA1255857)
Chan Zuckerberg Initiative (DAF2021-225261)
UKRI | Medical Research Council (MC_ST_00035)
UKRI | Medical Research Council (MR/Ro15635/1)
National Science Foundation (2348683)
Silicon Valley Community Foundation (https://doi.org/10.13039/100014989)
Article History
Received: 28 July 2025
Revised: 15 December 2025
Accepted: 16 December 2025
First Online: 27 March 2026
Disclosure and competing interests statement
: NOC is co-founder, shareholder, and management consultant for PhenoTherapeutics Ltd. SS and AEC serve as scientific advisors for companies that use image-based profiling and Cell Painting (AEC: Recursion, SyzOnc, Quiver Bioscience, SS: Waypoint Bio, Dewpoint Therapeutics, Deepcell) and receive honoraria for occasional scientific visits to pharmaceutical and biotechnology companies. The remaining authors declare no competing interests.